title: Making it to manufacturing. The potential success of broadly neutralizing monoclonal antibodies for HIV prevention, treatment, and possibly even a cure could come at a cost.
authors.forename: Michael
authors.initials: M
authors.lastname: Dumiak
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D057134:Antibodies, Neutralizing / Q000276:immunology*; D019149:Bioreactors; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D006801:Humans
chemical_list: D016915:AIDS Vaccines; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing